EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study

Alison E Simmons iD, Afia Amoako, Alicia A Grima, Kiera R Murison, Sarah A Buchan iD, David N Fisman, Ashleigh R Tuite iD

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0283715 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift PLOS ONE, 2023. Verfasst von Alison E Simmons und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: COVID-19, Vaccine Efficacy. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research, University of Toronto.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Vaccines against SARS-CoV-2 have been shown to reduce risk of infection as well as severe disease among those with breakthrough infection in adults. The latter effect is particularly important as immune evasion by Omicron variants appears to have made vaccines less effective at preventing infection. Therefore, we aimed to quantify the protection conferred by mRNA vaccination against hospitalization due to SARS-CoV-2 in adolescent and pediatric populations.

Methods

We retrospectively created a cohort of reported SARS-CoV-2 case records from Ontario’s Public Health Case and Contact Management Solution among those aged 4 to 17 linked to vaccination records from the COVaxON database on January 19, 2022. We used multivariable logistic regression to estimate the association between vaccination and hospitalization among SARS-CoV-2 cases prior to and during the emergence of Omicron.

Results

We included 62 hospitalized and 27,674 non-hospitalized SARS-CoV-2 cases, with disease onset from May 28, 2021 to December 4, 2021 (Pre-Omicron) and from December 23, 2021 to January 9, 2022 (Omicron). Among adolescents, two mRNA vaccine doses were associated with an 85% (aOR = 0.15; 95% CI: [0.04, 0.53]; p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Vaccine EfficacyAdolescentAdultChildHumansCOVID-19 VaccinesHospitalizationmRNA VaccinesOntarioRetrospective StudiesSARS-CoV-2

Substanzen

COVID-19 VaccinesmRNA Vaccines

Autor:innen und Institutionen

  • Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
  • Public Health Ontario, Toronto, Ontario, Canada.
  • Centre for Immunization Readiness, Public Health Agency of Canada, Ottawa, Ontario, Canada.

ORCID-Profile: Alison E Simmons, Sarah A Buchan, Ashleigh R Tuite

Förderung

  • Canadian Institutes of Health Research
  • University of Toronto

Zitieren

APA

Simmons, A. E., Amoako, A., Grima, A. A., Murison, K. R., Buchan, S. A., Fisman, D. N., & Tuite, A. R. (2023). Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study. PLOS ONE. https://doi.org/10.1371/journal.pone.0283715

Vancouver

Simmons AE, Amoako A, Grima AA, Murison KR, Buchan SA, Fisman DN, et al. Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study. PLOS ONE. 2023. doi:10.1371/journal.pone.0283715

BibTeX
@article{Simmons2023,
  author = {Simmons, Alison E and Amoako, Afia and Grima, Alicia A and Murison, Kiera R and Buchan, Sarah A and Fisman, David N and Tuite, Ashleigh R},
  title = {Vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Ontario, Canada: A retrospective cohort study},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0283715}
}
Kostenlos starten →